Can a person battling Candida albicans take EpiCor™ since it is derived from yeast?
A. The yeast that EpiCor™ is derived from is common baker’s yeast. Having worked with patients with yeast sensitivity and those addressing Candida albicans infections, I do not routinely find a significant cross reactivity with yeast-derived substances. Certainly, the potential is theoretically present for a few select individuals to experience reactivity symptoms, yet I have not found this to be the case in clinical practice. In fact, experts in the field believe that the likelihood for reactivity is minimal, otherwise the ubiquitous nature of baker’s yeast would cause reactivity in the populace on an ongoing basis. EpiCor is such a powerful immune modulator that it would most likely benefit most individuals suffering from candidiasis.
